48.42 +0.20 (0.41%)
Pre-market: 8:05AM EDT
|Bid||48.27 x 1200|
|Ask||48.46 x 1300|
|Day's range||47.65 - 48.47|
|52-week range||44.30 - 63.69|
|Beta (3Y monthly)||0.79|
|PE ratio (TTM)||15.35|
|Earnings date||25 Jul 2019|
|Forward dividend & yield||1.64 (3.61%)|
|1y target est||56.10|
In a descriptive analysis, addition of Empliciti to pomalidomide and dexamethasone reduced risk of death by 46% among patients with RRMM
The Board of Directors of Bristol-Myers Squibb Company today declared a quarterly dividend of forty one cents per share on the $.10 par value Common Stock of the corporation.
Bristol-Myers Squibb Company (BMY) today announced data from a Phase IV mechanistic study exploring differences in the cellular and molecular mechanisms by which ORENCIA® (abatacept) and another treatment, adalimumab, interfere with disease progression in moderate-to-severe early rheumatoid arthritis (RA) patients seropositive for certain autoantibodies. Among 80 adult patients with early (≤ 12 months from symptom onset) moderate-to-severe RA who had never been treated with a biologic medication and tested positive for autoantibodies called anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF), numerically higher efficacy responses were seen with ORENCIA at week 24. ACR 20/50/70 scores for adalimumab were 63, 45 and 30, respectively.
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $47.63, marking a +1.62% move from the previous day.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
Bristol-Myers Squibb (BMY) closed at $46.15 in the latest trading session, marking a -1.03% move from the prior day.
The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.